Neoadjuvant therapy of rectal cancer new treatment perspectives

Tumori

Volumn 90, Issue 4, 2004, Pages 373-378

  De Paoli, Antonino ^a   Innocente, Roberto ^a   Buonadonna, Angela ^a   Boz, Giovanni ^a   Sigon, Roberto ^a   Canzonieri, Vincenzo ^a   Frustaci, Sergio ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Combined modality therapy; Neoadjuvant therapy; Rectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED; VASCULOTROPIN ANTIBODY;

ADJUVANT CHEMOTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DIARRHEA; DRUG SCREENING; HUMAN; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NONHUMAN; PREOPERATIVE TREATMENT; RECTUM CANCER; REVIEW; SIDE EFFECT;

EID: 4644275714     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160409000402     Document Type: Review

References (50)

1. Douglass HO Jr, Moertel CG, Mayer RJ, Thomas PR, Lindblad AS, Mittleman A, Stablein DM, Bruckner HW: Survival after postoperative combination treatment of rectal cancer. N Engl J Med, 315: 1294-1295, 1986.
2. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med, 324: 709-715, 1991.
3. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA, 264: 1444-1450, 1990.
4. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, Fisher ER, Caplan R, Jones J, Lerner H: Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer, results from NSABP protocol R-01. J Natl Cancer Inst, 80: 21-29, 1988.
5. Gastrointestinal Tumor Study Group: Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol, 10: 549-557, 1992.
6. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA: Improving adjuvant therapy for rectal cancer by combining protacted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med, 331: 502-507, 1994.
7. Tepper JE, O'Connell MJ, Petroni GR, Hollis D, Cooke E, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA: Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol, 15: 2030-2039, 1997.
8. Smalley SR, Benedetti J, Williamson S, Robertson J, Fisher B, Martenson J, Benson AB, Robert M, Cripps C, MacDonald J for the Southwest Oncology group: Intergroup 0144-Phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV. Proc ASCO, 22: 251 (#1006), 2003.
9. Swedish Rectal Cancer Trial: Improved survival with preoperative radiation in resectable rectal cancer. N Engl J Med, 336: 980-987, 1997.
10. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ, Dutch Colorectal Cancer Group: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med, 345: 638-646, 2001.
11. Holm T, Singnomklao T, Rutqvist LE, Cedermark B: Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomised trials. Cancer, 78: 968-976, 1996.
12. Holm T, Rutqvist LE, Johansson H, Cedermark B: Postoperative mortality in rectal cancer treated with or without preoperative radiotherapy: causes and risk factors. Br J Surg, 83: 964-968, 1996.
13. Dahlberg M, Glimelius B, Graf W, Pahlman L: Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis Colon Rectum, 41: 543-551, 1998.
14. Minsky BD: Adjuvant therapy of rectal cancer. Semin Oncol, 26: 540-544, 1999.
15. Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Reichman B, Saltz L, Sigurdson ER, Frankel J: Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol, 10: 1218-1224, 1992.
16. Bosset JF, Calais G, Daban A, Pierart M, Radosevic-Jelic L, Maingon P, Bardet E, Briffaux A, for the EORTC - Radiotherapy Group: Does the addition of chemotherapy to preoperative radiation increase acute toxicity in patients with rectal cancer: report of 22921 EORTC phase III trial. Proc ASCO, 22: 249 (#1179), 2003.
17. Cionini L, Cartei F, Manfredi B, Laliscia C, Sainato A, Valentini V, Luppatelli M, Pizzi GB, Osti M, Santoni R: Randomised study of preoperative chemoradiation (CT-RT) in locally advanced rectal cancer. Preliminary results. Int J Radiat Oncol Biol Phys, 45 (3 Suppl): 178, 1999.
18. Hyams DM, Mamounas EP, Petrelli N, Rockette H, Jones J, Wieand HS, Deutsch M, Wickerham L, Fisher B, Wolmark N: A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum, 40: 131-139, 1997.
19. Sauer R, Fietkau R, Martus P, Raab R, Roedel C, Wittekind C: Adjuvant and neoadjuvant radiochemotherapy for advanced rectal cancer: first results of the German multicentric phase III trial. Int J Radiat Oncol Biol Phys, 48: 119 (abst), 2000.
20. Mohiuddin M, Hayne M, Regine WF, Hanna N, Hagihara PF, McGrath P, Marks GM: Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Rad Oncol Biol Phys, 48: 1075-1080, 2000.
21. Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey JN, Lynch P, Ellis LM, Wolff R, Lenzi R, Abbruzzese J, Pazdur R, Hoff PM, Allen P, Brown T, Skibber J: Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol, 24: 107-112, 2001.
22. Sigon R, Canzonieri V, De Paoli A, Buonadonna A, Pasquotti B, Bonasegale A, Curcio A, Rossi C: Preoperative chemoradiation for locally advanced rectal cancer. Surgical procedure and pathological findings. Proceedings Third International Conference: perspectives in colorectal cancer. Dublin, June 7-9, abst 39, 2001.
23. Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, Wagman R, Saltz LB, Wong WD: Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg, 194: 131-136, 2002.
24. Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, Cellini F, Barbaro B, Cogliandolo S, Nuzzo G, Doglietto GB, Ambesi-Impiombato F, Cosimelli M: Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys, 53: 664-674, 2002.
25. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol, 45: 291-297, 2000.
26. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H: X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res, 5: 2948-2953, 1999.
27. Dunst J, Reese T, Sutler T, Zuhlke H, Hinke A, Kolling-Schlebusch K, Frings S: Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol, 20: 3983-3991, 2002.
28. Dunst J, Reese T, Hoelscher T, Rudat V, Wulf J, Mose S, Hinke A, Debus J: Capecitabine combined with radiotherapy as neoadjuvant treatment of locally advanced rectal cancer. Proc ASCO, 22: 277, 2003.
29. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res, 51: 5579-5586, 1991.
30. Jackman AL, Calvert AH: Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol, 6: 871-881, 1995.
31. Valentini V, Doglietto GB, Morganti AG, Turriziani A, Smaniotto D, De Santis M, Ratto C, Sofo L, Cellini N: Preoperative chemoradiation with raltitrexed (Tomudex) for T2/N+ and T3/N+ rectal cancers: a phase I study. Eur J Cancer, 37: 2050-2055, 2001.
32. Gambacorta MA, Valentini V, Morganti AG, Smaniotto D, Mantini G, Micciche F, Ratto C, Doglietto GB, De Paoli A, Rossi C, Cellini N, Garcia-Vargas J: Preoperative chemoradiation with raltitrexed (Tomudex) in T3-4 rectal carcinoma: a phase I-II study. Int J Radiat Oncol Biol Phys, 54 (2 Suppl): 248, 2002.
33. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol, 52: 1855-1865, 1996.
34. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18: 2938-2947, 2000.
35. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fouraier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol, 18: 136-147, 2000.
36. Blackstock A, Hess S: Oxaliplatin: in vitro and in vivo evidence of its radiation sensitizing activity - preclinical observations relevant to ongoing clinical trials. Proc Am Assoc Cancer Res, 41: 53, 2000.
37. Aschele C, Friso ML, Pucciarelli S, Sartor L, Lonardi S, De Salvo G, Fabris G, Da Dalt G, Ranzato R, Bruttoco A, Neri D, Finco C, Monfardini S: A phase II study of weekly oxaliplatin (OXA), 5-fluorouracil continuous infusion (CI) and preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC). Proc ASCO, 21: 132A, 2002.
38. Gerard JP, Chapet O, Nemoz C, Romestaing P, Mornex F, Coquard R, Barbet N, Atlan D, Adeleine P, Freyer G: Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin- containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol, 21: 1119-1124, 2003.
39. Valentini V, Morganti AG, Gambacorta MA, Luzi S, Smaniotto D, Micciche F, Mantini G, Garcia-Vargas JE, Coco C, Cogliandolo S, Picciocchi A, Cellini N: Raltitrexed ("Tomudex") and oxaliplatin ("Tomox") preliminary results of a phase II study of chemoradiation with pre-operative treatment of stage II/III resectable rectal cancer. Proc ASCO, 21: 151A, 2002.
40. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R: Phase I-II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol, 21: 3098-3104, 2003.
41. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355: 1041-1047, 2000.
42. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med, 343: 905-914, 2000.
43. Rich TA, Kirichenko AV: Camptothecin radiation sensitization: Mechanisms, schedules, and timing. Oncology (Huntingt), 12 (8 Suppl 6): 114-120, 1998.
44. Mitchel EP, Anne P, Fry R, Palazzo J, Hauck W, Fishel R, Goldstein S, Isenberg G, Edmunston T, Curran W: Chemoradiation with CPT-11, 5FU in neoadjuvant treatment of locally advanced recurrent adenocarcinoma of the rectum: a phase I/II study update. Proc ASCO, 22: 262A, 2003.
45. Mehta VK, Cho C, Ford JM, Jambalos C, Poen J, Koong A, Lin A, Bastidas JA, Young H, Dunphy EP, Fisher G: Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys, 55: 132-137, 2003.
46. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol, 19: 183-232, 1995.
47. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G: Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res, 6: 2053-2063, 2000.
48. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R: Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell, 10: 2493-2506, 1999.
49. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumours and other disorders. Cancer Res, 57: 4593-4599, 1997.
50. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature, 394: 287-291, 1998.